

1 **Prevalence and risk factors of disability and anxiety in a retrospective cohort of**
2 **432 survivors of Coronavirus Disease-2019 (Covid-19) from China**

3
4 Siyi Zhu^{1,2,¶}; Qiang Gao^{1,2,¶}; Lin Yang^{1,2,¶}; Yonghong Yang^{1,2,¶}; Wenguang Xia⁴; Xiguo
5 Cai⁵; Yanping Hui⁶; Di Zhu⁷; Yanyan Zhang⁸; Guiqing Zhang⁹; Shuang Wu¹⁰; Yiliang
6 Wang¹¹; Zhiqiang Zhou¹²; Hongfei Liu¹³; Changjie Zhang¹⁴; Bo Zhang¹⁵; Jianrong
7 Yang¹⁶; Mei Feng³; Zhong Ni³; Baoyu Chen¹; Chunping Du^{1,2}; Hongchen He^{1,2}; Yun
8 Qu^{1,2}; Quan Wei^{1,2}; Chengqi He^{1,2,17,¶*}; Jan D. Reinhardt^{17,18,19,20,¶*}.

9

10

11 ¹ Rehabilitation Medical Center, West China Hospital, Sichuan University, Chengdu,
12 China.

13 ² Rehabilitation Medicine Key Laboratory of Sichuan Province, Sichuan University,
14 Chengdu, China.

15 ³ Department of Critical Care Medicine, West China Hospital, Sichuan University,
16 Chengdu, China.

17 ⁴ Hubei Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan,
18 Hubei, China.

19 ⁵ Henan Provincial People's Hospital, Zhengzhou, Henan, China.

20 ⁶ The Second Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xian,
21 Shanxi, China.

22 ⁷ Zhejiang provincial People's Hospital, Hangzhou, Zhejiang, China.

23 ⁸ Qilu Hospital of Shandong University, Jinan, Shandong, China.

24 ⁹ The First Affiliated Hospital, School of Medicine, Shihezi University, Xinjiang, China.

25 ¹⁰ The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.

26 ¹¹ Chongqing Three Gorges Central Hospital, Chongqing, China.

27 ¹² Inner Mongolia Autonomous Region Baotou Central Hospital, Baotou, China.

28 ¹³ General Hospital of General Bureau of Agricultural Reclamation of Heilongjiang
29 Province, Harbin, China.

30 ¹⁴ The Second Xiangya Hospital of Central South University, Changsha, China.

31 ¹⁵ Nanchong central hospital, Nanchong, Sichuan, China.

32 ¹⁶ Garze People's Hospital, Garze Tibetan Autonomous Prefecture, Sichuan, China.

33 ¹⁷ Institute for Disaster Management and Reconstruction of Sichuan University and
34 Hong Kong Polytechnic University, Sichuan University, Chengdu, China.

35 ¹⁸ Swiss Paraplegic Research, Switzerland.

36 ¹⁹ Department of Health Sciences and Medicine, University of Lucerne, Switzerland.

37 ²⁰ Committee for Rehabilitation Disaster Relief, International Society for Physical and
38 Rehabilitation Medicine, Geneva, Switzerland.

39

40 ¶S Zhu, Q Gao, L Yang, Y Yang, Q Wang, C He and JD Reinhardt contributed equally
41 and share first authorship.

42

43 *Correspondence to: Prof Chengqi He MD, Rehabilitation Medical Center, West China
44 Hospital, No.37 Guoxue Alley, Wuhou District, Chengdu, China hxkfhcq@126.com

45 or Prof Jan D. Reinhardt PhD, Institute for Disaster Management and Reconstruction of
46 Sichuan University and Hong Kong Polytechnic University, Sichuan University, 122
47 Huanghe Zhong Lu, Chengdu 610041, Sichuan, China jan.reinhardt@paraplegie.ch.

48 **Abstract**

49
50 **Objective:** To estimate the prevalence of disability and anxiety in Covid-19 survivors at
51 discharge from hospital and analyze relative risk by exposures.

52 **Design:** Multi-center retrospective cohort study.

53 **Setting:** Twenty-eight hospitals located in eight provinces of China.

54 **Methods:** A total of 432 survivors with laboratory-confirmed SARS CoV-2 infection
55 participated in this study. At discharge, we assessed instrumental activities of daily living
56 (IADL) with Lawton's IADL scale, dependence in activities of daily living (ADL) with the
57 Barthel Index, and anxiety with Zung's self-reported anxiety scale. Exposures included
58 comorbidity, smoking, setting (Hubei vs. others), disease severity, symptoms, and length
59 of hospital stay. Other risk factors considered were age, gender, and ethnicity (Han vs.
60 Tibetan).

61 **Results:** Prevalence of at least one IADL problem was 36.81% (95% CI: 32.39-41.46).
62 ADL dependence was present in 16.44% (95% CI: 13.23-20.23) and 28.70% (95% CI:
63 24.63- 33.15) were screened positive for clinical anxiety. Adjusted risk ratio (RR) of IADL
64 limitations (RR 2.48, 95% CI: 1.80-3.40), ADL dependence (RR 2.07, 95% CI 1.15-3.76),
65 and probable clinical anxiety (RR 2.53, 95% CI 1.69-3.79) were consistently elevated in
66 survivors with severe Covid-19. Age was an additional independent risk factor for IADL

67 limitations and ADL dependence; and setting (Hubei) for IADL limitations and anxiety.

68 Tibetan ethnicity was a protective factor for anxiety but a risk factor for IADL limitations.

69 **Conclusion:** A significant proportion of Covid-19 survivors had disability and anxiety at

70 discharge from hospital. Health systems need to be prepared for an additional burden

71 resulting from rehabilitation needs of Covid-19 survivors.

72 **Keywords:** COVID-19; Rehabilitation; Disability; Activities of Daily Living; Mental Health;

73 Anxiety.

74

75 **Introduction**

76 With rapidly increasing numbers of confirmed cases and deaths caused by the

77 Coronavirus Disease-2019 (Covid-19) pandemic, clinical outcomes research has almost

78 exclusively focused on disease progression and mortality[1]. With the case fatality rate

79 estimated to lie somewhere between 0.56 and 9.38 percent globally (95% prediction

80 interval, $I^2 = 100\%$),[2] it is obvious however that a vast majority of people actually

81 survive Covid-19. A substantial proportion of survivors have experienced severe disease

82 episodes requiring hospitalization and - in a considerable number of cases - intensive

83 care including mechanical ventilation[3]. In addition, contracting a potentially fatal

84 disease is stressful and can cause anxiety and other psychiatric manifestations in many

85 patients.[4] It would be naïve to assume that health problems just disappear upon

86 discharge from acute care or when viral RNA is no longer detectable, and equally naïve

87 to take planned and systematic follow up of patients for granted.[5, 6] Yet, the burden of

88 disease resulting from physical and psychological sequelae of Covid-19 in patients

89 surviving the disease as well as potential long-term adverse effects from treatments
90 including steroids such as Dexamethasone are just beginning to catch attention[7, 8].
91 Globally, respiratory infections and tuberculosis assume already the fourth rank of all
92 diseases in terms of disability adjusted life years (DALYs) and the 17th rank in years
93 lived with disability (YLD). In infectious disease, they sadly rank first and second,
94 respectively.[9, 10] Covid-19 will increase this burden considerably and cause longer
95 term mental and physical health problems, work disability, and reduced quality of life in
96 survivors, frontline health professionals, and those quarantined.[11, 12] What we know
97 from the 2002/2003 Severe Acute Respiratory Syndrome (SARS) epidemic is not
98 encouraging. In Hong Kong for example, about 80 percent of SARS survivors still
99 needed follow-up treatment two years after the outbreak had been contained.[13]
100 The number of patients needing follow-up care and rehabilitation due to Covid-19 will be
101 unprecedented. Countries need to consider and plan for this additional long-term
102 challenge to the health system. It is important to understand risk factors for disability and
103 mental health problems now in order to direct scarce resources and meet windows of
104 opportunity for treatment. This study makes a first attempt to address this issue. We
105 aimed to (1) estimate the prevalence of disability and anxiety in Covid-19 survivors from
106 eight Provinces/centrally governed municipalities of the PR China at discharge from
107 acute inpatient treatment, and (2) investigate relative risk of adverse outcomes by
108 various determinants including gender, age, comorbidity, setting, ethnicity and disease
109 severity. Prevalence estimates are important to gain insight in the potential number of
110 patients needing follow-up care. Analyzing risk factors is instrumental in identifying
111 vulnerable groups and allocating resources for early interventions.

112 **Methods**

113 **Study design**

114 We conducted a multi-center retrospective cohort study. The study protocol was
115 approved by the ethics committee of West China Hospital, Sichuan University (2020-
116 273).

117 **Subjects**

118 Four hundred and thirty-two Covid-19 survivors were surveyed who had received
119 treatment in 28 designated hospitals in Hubei, Sichuan, Guizhou, Henan, Neimenggu
120 (inner Mongolia), Shandong, Hainan, and Chongqing from January 18 to March 15,
121 2020 and gave informed consent. Included were adults (≥ 16 years) who had laboratory-
122 confirmed SARS coronavirus-2 (SARS CoV-2) infection and met the diagnostic criteria
123 of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version
124 7) issued by the National Health Commission of the PR China (Third edition).[14]
125 Survivors further needed to be in stable medical condition and have been discharged or
126 be about to be discharged from the participating centers. Excluded were patients with
127 pneumonia caused by other types of coronaviruses, seasonal influenza, bacteria, or
128 other not SARS CoV-2 etiology.

129 Patients were contacted by health professionals who were in charge of their treatment.
130 All health professionals were instructed on implementation of the study protocol,
131 informed consent procedures, and possible sources of bias by videoconference.

132 **Measures**

133 *Outcomes:* Outcomes were disability and anxiety. Cut off date for outcome assessment
134 was April 7, 2020. Disability was measured in two ways: (1) Limitations in instrumental
135 activities of daily living (IADL) were assessed with the Lawton IADL scale[15] and

136 classified into no limitations vs. one or more limitations (primary outcome). An index of
137 the number of reported IADL limitations was also created. (2) Dependence in activities of
138 daily living (ADL) was measured with the Barthel Index[16] and classified into severe or
139 moderate dependence vs. mild dependence/independence.[17] Anxiety was evaluated
140 with Zung's Self-Reported Anxiety Scale[18] (SAS) and classified into probable clinical
141 anxiety disorder vs. not according to a conservative cutoff recommended for
142 research.[19] Outcome data were patient-reported and collected with an online
143 questionnaire.

144 *Risk factors:* Clinical and demographic data were extracted from hospital records by
145 participating health professionals. Current smoking status was self-reported by
146 participants. Demographic data included age, gender, province (Hubei vs. others), and
147 ethnicity (Han vs. Tibetan). Having received treatment in Hubei was considered a risk
148 factor because of the particular situation in Hubei which was the epicenter of the
149 epidemic in China representing about 80 percent of confirmed cases. Ethnicity was
150 included as a significant proportion of the sample from Sichuan was from the Tibetan
151 ethnic group, and belonging to a minority ethnic group is known to be associated with
152 health outcomes in other disease. Clinical data included comorbidity, disease severity,
153 symptoms at admission, scope of pneumonia, and length of inpatient stay. Recorded
154 comorbid conditions included COPD, chronic bronchitis, pulmonary fibrosis,
155 hypertension, diabetes, cardiovascular disease, kidney disease, hepatitis, rheumatism,
156 and gout. Degree of Covid-19 severity was classified according to the Chinese
157 standard.[14] Patients were defined as severe cases when they met one of the following
158 criteria at any time during hospitalization: acute respiratory distress, respiratory rate ≥ 30
159 breath/min; pulse oxygen saturation (SpO₂) $\leq 93\%$ at rest; arterial blood partial pressure

160 of oxygen/fraction of inspired oxygen ($\text{PaO}_2/\text{FiO}_2$) ≤ 300 mmHg (1 mmHg = 0.133 kPa);
161 respiratory failure requiring mechanical ventilation; septic shock; failure of other organs
162 requiring ICU treatment. Symptoms recorded at admission included fever, cough,
163 diarrhea, fatigue and pain. Scope of pneumonia was noted as uni- or bilateral per
164 radiographic findings. Data on length of hospital stay were available for 408 patients
165 (94.44%).

166 **Sample size calculation**

167 Sample size to detect a two-fold relative risk for reporting one or more IADL limitations in
168 the severe disease group as compared to the non-severe group with a power of 80%
169 and alpha error of 5% was estimated under the following assumptions: 0.2 ratio of
170 severe to non severe group (based on patients received at our own center), 15 percent
171 prevalence of outcome in non-severe group. This yielded a minimal sample size of 401
172 (67 severe, 334 non-severe).

173 **Analysis**

174 Prevalence of limitations in IADL, ADL dependence, and anxiety for the full sample and
175 by disease severity were provided with 95% confidence intervals (CIs) estimated from
176 logistic regression. Risk ratios (RR) and 95% CIs for gender, age group (≤ 50 , 50-60, >
177 60 years), province (others vs. Hubei), ethnicity (Han vs. Tibetan), comorbid health
178 conditions (none, one, multiple), disease severity (non-severe vs. severe), symptoms
179 (≤ 1 , > 1) at admission, and infection scope (unilateral vs. bilateral) were estimated with
180 log-linear Poisson regression with robust standard errors.[20] Since longer time of being
181 hospitalized could increase anxiety, length of hospital stay was included in the anxiety-
182 model in addition. For each outcome unadjusted RR and RR adjusted for all other

183 potential risk factors evaluated were provided. Zero-inflated Poisson (ZIP) regression
184 was used to estimate the effect of risk factors on the extent of IADL limitations. ZIP
185 regression assumes that there are two groups in the population from which the data are
186 sampled, one which always has zero counts, and one which may have zero or higher
187 counts. Young people with non-severe disease who have no comorbidity may never
188 develop IADL limitations, while other groups may develop (additional) IADL limitations
189 due to factors associated with disease progression. ZIP regression simultaneously
190 performs logistic and Poisson regression making two types of predictions: (1) prediction
191 of excess zeros assuming a binary dependent variable (no IADL limitations vs. one or
192 more), (2) prediction of the count portion (number of experienced IADL limitations).
193 Predictors included in the logistic part were the following background factors: age group
194 and interaction of age and disease severity, province, ethnicity, smoking, and comorbid
195 conditions. Predictors included in the count part were potential drivers of disease
196 consequences: disease severity, interaction of age and disease severity, symptoms, and
197 infection scope. Vuong's test confirmed fit of the ZIP model.
198 All analyses were performed with Stata 14 (Stata corporation, Texas, USA).

199 **Results**

200 Demographic and clinical characteristics and prevalence of outcomes of the study
201 participants are provided in Table 1. Median age was 49 (IQR 35-60) and 49% were
202 female. About one third of the study participants were classified as severe cases. Fever,
203 cough, and fatigue were the most common symptoms at admission. A majority had no
204 pre-existing health condition and were non-smokers. Patients with severe Covid-19 were
205 older, were more often from Hubei and belonged to the Han majority, presented with

206 more symptoms, had more often bilateral pneumonia, and stayed in the hospital for a
 207 longer time. More pre-existing health conditions were present in severe cases, but the
 208 percentage of smokers was lower. Over one third of Covid-19 survivors had at least one
 209 IADL limitation, about 15 percent had at least moderate ADL dependence, and six
 210 percent were severely dependent. Probable clinical anxiety disorder was found in about
 211 29 percent of the population. Prevalence of all outcomes was more than four times
 212 higher in survivors of severe Covid-19 than in those with non-severe disease.

213 **Table 1. Demographic and Clinical Characteristics of study participants (I) and prevalence of outcomes (II)**

I. Demographic and clinical characteristics	All participants (N=432)	By disease severity	
		non-severe (n=285, 65.97%)	severe (n=147, 34.03%)
Female sex – no./total no. (%)	207/432 (47.92)	138/285 (48.42)	69/147 (46.94)
Age			
Median (IQR) in years	49 (35-60)	45 (32.5-54.5)	57 (47-68)
Distribution – no./total no. (%)			
< 50	218/431 (50.58)	173/284 (60.92)	45/147 (30.61)
50-60	108/431 (25.06)	69/284 (24.30)	39/147 (26.53)
> 60	105/431 (24.36)	42/284 (14.79)	63/147 (42.86)
Province – no./total no. (%)			
Hubei	169/432 (39.12)	73/285 (25.61)	96/147 (65.31)
Sichuan	162/432 (37.50)	144/285 (50.53)	18/147 (12.24)
Chongqing	38/432 (8.80)	29/285 (10.18)	9/147 (6.12)
Henan	30/432 (6.94)	15/285 (5.26)	15/147 (10.20)
Guizhou	24/432 (5.56)	17/285 (5.96)	7/147 (4.76)
Other	9/432 (2.08)	7/285 (2.46)	2/147 (1.36)
Ethnicity – no./total no. (%)			

Han	360/432 (83.33)	220/285 (77.19)	140/147 (95.24)
Tibetan	72/432 (16.67)	65/285 (22.81)	7/147 (4.76)
Smoking history, yes – no./total no. (%)	62/432 (14.35)	46/285 (16.14)	16/147 (10.88)
Pre-existing comorbidity – no./total no. (%)			
none	300/432 (69.44)	226/285 (79.30)	74/147 (50.34)
one	79/432 (18.29)	37/285 (12.98)	42/147 (28.57)
multi	53/432 (12.27)	22/285 (7.72)	31/147 (21.09)
Symptoms on admission – no./total no. (%)			
Fever	249/432 (57.64)	125/285 (43.86)	124/147 (84.35)
Cough	257/432 (59.49)	139/285 (48.77)	118/147 (80.27)
Fatigue	153/432 (35.42)	70/285 (24.56)	83/147 (56.46)
Pain	68/432 (15.74)	40/285 (14.04)	28/147 (19.05)
Diarrhea	46/432 (10.65)	24/285 (8.42)	22/147 (14.97)
Bilateral infection scope^{&} - no./total no. (%)	362/432 (83.80)	221/285 (77.54)	141/147 (95.92)
Length of hospital stay[§]			
Median (IQR) in days	18 (12-25)	15 (11-22)	23 (15.5-31.61)
Distribution – no./total no. (%)			
1-14 days	160/408 (39.22)	130/268 (48.51)	30/140 (21.43)
>14 days	248/408 (60.78)	138/268 (51.49)	110/140 (78.57)
Discharge Destination[§] - no./total no. (%)			
Discharged home	278/412 (67.48)	215/269 (79.93)	63/143 (44.06)
Discharged to 14-day quarantine	128/412 (31.07)	52/269 (19.33)	76/143 (53.15)
Referred to other hospital	6/412 (1.46)	2/269 (0.74)	4/143 (2.80)
Mechanical Ventilation– no./total no. (%)			
No	395/411 (96.11)	268/268 (100.00)	127/143 (88.81)

Yes	16/411 (3.89)	0/268 (0.00)	16/143 (11.19)
II. Outcomes*			
Disability, percent (95% CI)			
One or more IADL limitations	36.81 (32.39-41.46)	18.25 (14.18-23.16)	72.79 (65.04-79.37)
Moderate ADL dependence	16.44 (13.23-20.23)	6.32 (4.01-9.80)	36.05 (28.71-44.11)
Severe ADL dependence	5.56 (3.75-8.15)	2.46 (1.17-5.06)	11.56 (7.31-17.82)
Anxiety, percent (95% CI)	28.70 (24.63-33.15)	13.33 (9.86-17.80)	58.50 (50.38-66.19)

214 [§]Scope of pneumonia as confirmed by radiography. [&]For 24 (5.56%) patients discharge date had not been
 215 entered in the data form. *Confidence intervals estimated from logistic regression. CI = confidence
 216 interval. IADL = instrumental activities of daily living. ADL = activities of daily living.

217
 218 Results on risk factors for disability and anxiety are displayed in Fig 1 and 2 (for detailed
 219 estimates see S1-3 Tables). Risk ratios for reporting at least one IADL limitation (Fig 1,
 220 upper panel) were increased in the older age groups, particularly in survivors aged older
 221 than 60 years, in patients from Hubei, and in survivors with severe Covid-19. The
 222 adjusted model also showed an elevated relative risk in survivors from the Tibetan
 223 ethnic group. Only in unadjusted models was the relative risk of having one or more
 224 IADL limitations clearly elevated in survivors with comorbidities, in patients with more
 225 symptoms at admission, and in those with bilateral infections. Both in unadjusted and
 226 adjusted models, the relative risk for ADL dependence (Fig 1 lower panel) was
 227 consistently increased in Covid-19 survivors aged older than 60 years, and in
 228 participants with severe disease course and more symptoms. All individual risk ratios

229 were higher in unadjusted models. Setting, comorbidity, and infection site played a role
230 in unadjusted analysis only.

231
232 **Fig 1. Disability (IADL limitations and ADL dependence) in relation to potential risk**
233 **factors.** Risk ratios and 95% confidence intervals. Estimated from log-linear Poisson
234 regression with robust standard errors; unadjusted risk ratios are estimated from
235 univariable model for the effect of the respective predictor on the outcome, adjusted risk
236 ratios are estimated from multivariable model containing all potential risk factors. IADL =
237 Instrumental Activities of Daily Living. ADL = Activities of Daily Living. CI=confidence
238 interval. Note: In the case of ADL dependence, the upper limit of the confidence interval
239 for the unadjusted estimate of age > 60 years has been truncated for better readability of
240 the other effects (see S1-3 Tables for details). Adjusted model and unadjusted model for
241 age have been estimated for 431 cases (because of one missing date of birth).

242
243 **Fig 2. Probable clinical anxiety in relation to potential risk factors.** Risk Ratios and
244 95% confidence intervals. Estimated from log-linear Poisson Regression with robust
245 standard errors; unadjusted risk ratios are estimated from univariable model for the
246 effect of the respective predictor on the outcome, adjusted risk ratios are estimated from
247 multivariable model containing all potential risk factors. The adjusted model has been
248 estimated for 407 cases (because of missing information regarding length of stay for 24
249 cases and one case with missing date of birth). [&]Unadjusted model estimated for 407
250 cases (because of missing information regarding length of stay for 24 cases and one
251 case with missing date of birth). CI=confidence interval.

252
13

253 Having severe Covid-19 was the strongest risk factor for probable clinically relevant
254 anxiety, followed by having received treatment in Hubei province (Fig 2). In turn,
255 belonging to the Tibetan group was associated with a largely decreased relative risk of
256 anxiety. There was a trend for an increased relative risk of anxiety in survivors who had
257 stayed in the hospital for more than 14 days. Older age, comorbidity, symptoms, and
258 scope of pneumonia played a role in unadjusted analysis only.

259 Table 2 show the results of the ZIP regression of the number of IADL limitations on risk
260 factors. Hospitalization in Hubei, Tibetan ethnicity, and multi-comorbidity were
261 associated with lower odds of having a zero count of IADL limitations. For all age
262 groups, odds for having zero IADL limitations were decreased in people with severe
263 Covid-19. This effect became however smaller with increasing age. Disease severity, its
264 interaction with age, and symptoms were associated with a greater number of health
265 problems. The joint effect of age and degree of severity of Covid-19 on the number of
266 IADL limitations from both parts of the model is illustrated in Fig 3. In all age groups
267 having a severe course of Covid-19 was associated with a higher number of self-
268 reported IADL limitations. Point estimates for survivors with non-severe and those with
269 severe disease were however closer in the oldest age group. CIs for the number of IADL
270 limitations in participants with non-severe and those with severe Covid-19 moved closer
271 in both older age groups and overlapped in survivors aged 61 years and older.

272

273 **Table 2. Results from zero-inflated Poisson regression of number of IADL limitations on potential risk factors**
274 **(n=431)**

I. Excess zeros: Prediction of having no IADL limitation	OR (95% CI)	SE	z
Age			

< 50	1 (reference)			
50-60	0.66 (0.24-1.78)	0.51	-0.82	
> 60	0.04 (0.01-0.10)	0.54	-6.19	
Disease severity and age group				
non-severe and < 50 years old	1 (reference)			
severe and < 50 years old	0.06 (0.02-0.17)	0.51	-5.43	
non-severe and 50-60 years old	1 (reference)			
severe and 50-60 years old	0.11 (0.04-0.32)	0.56	-4.02	
non-severe and > 60 years old	1 (reference)			
severe and > 60 years old	0.34 (0.10-1.16)	0.62	-1.72	
Province				
Other provinces	1 (reference)			
Hubei	0.09 (0.04-0.19)	0.37	-6.46	
Ethnicity				
Han	1 (reference)			
Tibetan	0.16 (0.06-0.41)	0.49	3.78	
Smoking history				
no	1 (reference)			
yes	1.78 (0.67-4.75)	0.50	1.15	
Comorbid conditions				
none	1 (reference)			
one	0.65 (0.29-1.43)	0.41	-1.08	
multi	0.33 (0.12-0.90)	0.51	-2.16	
II. Count: Number of IADL limitations				
	IRR (95% CI)	SE	z	
Disease severity (reference: non-severe)				
non severe	1 (reference)			
severe	1.64 (0.97-2.80)	0.45	1.84	

Disease severity and age group			
non-severe and < 50 years old	1 (reference)		
non-severe and 50-60 years old	1.76 (0.99-3.15)	0.52	1.92
non-severe and > 60 years old	2.91 (1.78-4.77)	0.73	4.24
severe and < 50 years old	1 (reference)		
severe and 50-60 years old	1.34 (1.03-1.74)	0.18	2.21
severe and > 60 years old	1.65 (1.33-2.05)	0.18	4.52
Symptoms, number			
<= 1	1 (reference)		
>1	1.34 (1.10-1.62)	0.13	2.98
Infection scope			
Unilateral	1 (reference)		
Bilateral	1.19 (0.89-1.61)	0.18	1.16

275 OR = odds ratio, CI = confidence interval, SE = standard error of coefficient, z = standardized coefficient, IRR =
 276 incidence rate ratio, IADL = instrumental activities of daily living.

277

278 **Fig 3. Effect of the interaction of age and disease severity on the number of**
 279 **predicted IADL problems (triangles) with 95% confidence intervals (capped lines).**

280 Estimated from zero-inflated Poisson regression. Predictions are adjusted for other
 281 factors in the model. Predictors included in the logistic part (excess zeros) were the
 282 following: age group, interaction of age and disease severity, setting (Hubei vs. other
 283 province), Tibetan ethnicity (reference: Han), smoking history, and comorbid conditions.
 284 Predictors included in the count part were: disease severity, interaction of age and
 285 disease severity, symptoms, and infection scope. The model has been estimated for 431
 286 cases (because of one missing date of birth).

287

288 Discussion

289 This retrospective cohort study found a considerable prevalence of functional limitations
290 and dependence as well as anxiety in Covid-19 survivors at about time of discharge
291 from acute inpatient treatment. Disease severity was a major independent risk factor for
292 all outcomes. Age was an additional risk factor for both disability outcomes, and setting
293 (Hubei) for IADL limitations and anxiety. Tibetan ethnicity was a strong protective factor
294 for anxiety but a risk factor for IADL limitations when it was adjusted for covariates.
295 Demographic and clinical characteristics of the study population were comparable to
296 other reports on Covid-19 patients from China [1, 21] with two exceptions: a higher
297 percentage was classified as severe cases and current smoking was more prevalent in
298 the non-severe disease group. An explanation for the higher percentage of severe cases
299 in the present study is that the applied criteria for classifying Covid-19 cases as severe
300 by the National Health Commission of the PR China are more liberal than the criteria for
301 severe community-acquired pneumonia by the American Thoracic Society and Infectious
302 Disease Society of America[22] used by Guan et al.[21] The lower prevalence of
303 smokers in participants with severe disease was unexpected and contradicts previous
304 evidence in this regard.[21] A possible explanation is that current smoking status was
305 self-reported and participants with more severe disease outcomes did not reveal their
306 true smoking status, perhaps for fear of being stigmatized and held responsible for
307 contracting SARS CoV-2 or the severity of Covid-19.
308 We found a high prevalence of disability and anxiety, particularly in severe cases.
309 Almost three quarters of severe Covid-19 survivors experienced at least one IADL
310 problem and more than one third had at least moderate ADL dependence. The six

311 percent of the overall sample with severe ADL dependence are of particular concern
312 since severe functional dependence has been a reliable predictor of mortality in
313 populations with other health conditions.[23] No other original study directly investigated
314 disability outcomes related to Covid-19 so far. Follow up studies of SARS and Middle
315 East Respiratory Syndrome (MERS) survivors have however shown that decreased
316 exercise capacity and distance walked, fatigue, sleeping problems, shortness of breath,
317 reduced self-rated health, work disability, and structural damage (e.g. osteonecrosis)
318 from corticosteroids were prevalent in survivors even years after onset of symptoms.[11,
319 24, 25] In addition, access to health care, quality of services, and employment
320 opportunities of former SARS patients were compromised by enduring stigma[13, 26].
321 Our findings imply that a large proportion of Covid-19 survivors, particularly those who
322 experienced severe disease episodes are in need of follow up care and rehabilitation
323 services. This proportion may be reduced by the integration of early rehabilitation
324 interventions into acute care[27, 28].

325 Probable clinical anxiety disorder was found in one third of the overall sample and its
326 prevalence was almost four-fold increased in severe as compared to non-severe cases.
327 Previous studies on mental health in the Covid-19 pandemic have been conducted in
328 the general population[29, 30] and health professionals[31] but not in the patient
329 population. Studies in SARS survivors have however reported highly elevated long-term
330 psychiatric morbidity[32] and demonstrated adverse effects on the mental health of
331 caregivers.[11] Our findings point to the need of psychological counseling during acute
332 care and mental health follow-up in many Covid-19 survivors to mitigate suffering and
333 prevent the manifestation of psychiatric disorders.

334 Major risk factors for mortality due to Covid-19[1, 33] were also major risk factors of
335 disability: older age and severe disease course both independently increased the
336 relative risk of IADL limitations and ADL dependence. However, comorbidity[34] had an
337 adverse effect on disability outcomes in unadjusted analysis only. Though attenuated,
338 disease severity continued to play a major role when it was adjusted for age, co-
339 morbidity, and other potential confounders demonstrating an additional effect of Covid-
340 19 when other known risk factors for disability were held statistically constant. In all age
341 groups having severe Covid-19 was associated with a higher number of self-reported
342 IADL limitations. For survivors aged over 60 years we found that the extent of IADL
343 limitations was more similar in those with non-severe and severe Covid-19 than in the
344 other age groups. Accordingly, the oldest participants with non-severe Covid-19 were
345 more similar to survivors with severe disease in the younger age groups. There are two
346 possible explanations for this phenomenon that deserve further scrutiny: First, older
347 people have already more activity limitations before they acquire Covid-19. Second, a
348 non-severe disease course has a greater effect on IADL limitations for them.

349 Persistence of this effect when it was adjusted for comorbidity speaks for the latter
350 explanation. Having been treated in hospitals of Hubei province where Covid-19 spread
351 first and overwhelmed an unprepared health system was furthermore associated with
352 adverse disability outcomes, particularly IADL limitations. Moreover, belonging to the
353 Tibetan ethnic minority predicted worse IADL outcomes when it was controlled for other
354 potential risk factors. Given that the Tibetan population of Sichuan province mainly lives
355 in rural, mountainous areas, both findings point at the role that environmental factors
356 including the availability and accessibility of targeted services play in the disablement
357 process.[35] Our findings indicate that priority in rehabilitation resource allocation should

358 be given to patients with severe disease course, older people, and those living in
359 environments with restricted accessibility of services.

360 Regarding anxiety, outstanding independent risk factors were severity of Covid-19 and
361 setting, i.e. having been hospitalized in Hubei province. Apart from the specific situation
362 in hospitals in Hubei, insecurity about causes, transmission patterns, and prognosis
363 when Covid-19 first occurred likely contributed to this finding. Moreover, we found a
364 trend for longer length of hospital stay being independently associated with increased
365 relative risk of anxiety. In contrast to disability outcomes, Tibetan ethnicity was a
366 consistent protective factor in unadjusted as well as adjusted models of anxiety.

367 Possible explanations are cultural factors including larger families (due to the non
368 application of China's one child policy to this group) and greater social cohesion and
369 support. This finding needs further exploration. Our results point towards heightened
370 need for psychological support in patients who experienced severe disease episodes
371 and people from areas hardest hit by the Covid-19 pandemic.

372 **Study Limitations**

373 The present study has limitations. First, baseline data for the outcomes analyzed here
374 were not available. Because of this we cannot rule out that patients had disability or
375 anxiety before they contracted Covid-19, indeed having disability may have made
376 people more vulnerable to the disease [36-38]. However, most patients first presented
377 already with severe symptoms and baseline information collected before admission is
378 rare in any disease. Baseline information on comorbidity is thus as close as we get to
379 baseline disability and the effects of disease severity on outcomes remained consistent
380 when adjusted for baseline comorbidity in our analysis. Second, we may be criticized for
381 not having employed some kind of control group. An appropriate control group for the

382 effects and population under investigation is however difficult to define and to establish.
383 Age and gender matched general population controls are surely not appropriate
384 because of the lack of hospitalization. Investigating patients who have been hospitalized
385 for some other disease would not help disentangle the effects of disease and
386 hospitalization. Quarantined persons suspected for Covid-19 or those treated at home
387 may make up an interesting comparator but are difficult to access. We believe that our
388 comparison of patients with severe and non-severe Covid-19 nonetheless provides initial
389 evidence for the potential impact of the disease and is an important starting point in
390 investigating this population's rehabilitation needs. Third, outcome data were self-
391 reported by patients due to the lack of options for objective measurement. Survivors thus
392 may have under- or overestimated their physical abilities. Patient-reported outcome
393 measures have however not been used in this population before to the best of our
394 knowledge, making it difficult to appraise if and to what degree this kind of problem
395 existed. Fourth, psychiatric confirmation of anxiety in those screened positive was not
396 possible. Fifth, this study evaluated outcomes at discharge and conclusions about
397 longer-term prevalence, spontaneous recovery, and chronic manifestations cannot be
398 drawn at this point and further follow-up of the cohort is therefore indicated.

399 **Recommendations**

400 In spite of these limitations, there are several recommendations that can be derived from
401 our findings. First, awareness about possible functional and psychological
402 consequences of Covid-19 needs to be raised in patients, care providers, and health
403 policy makers[28]. Second, early psychological[39] and pulmonary rehabilitation
404 interventions including mobilization and exercise[27, 28, 40] which have been
405 investigated in other health conditions could be effective and important to meet

406 therapeutic windows; consequently their application (besides pharmacological
407 treatments) needs to be studied in the population of Covid-19 patients, particularly those
408 with severe disease. Third, this involves a better integration of primary care and
409 psychiatric and rehabilitation services which is unfortunately lacking in many lower as
410 well as higher resourced countries including China.[41] Fourth, systematic community
411 follow up and two-way referral systems between community health centers and
412 specialized hospital units, another weak point of many health systems, need to be
413 strengthened.[41] Fifth, we recommend that future prospective cohort studies in Covid-
414 19 survivors include functional and psychiatric outcomes.

415 **Conclusion**

416 A significant proportion of Covid-19 survivors had disability and anxiety at discharge
417 from hospital. Disease severity was the only independent risk factor with consistent
418 adverse effects on all outcomes. Health systems need to be prepared for an additional
419 long-term burden due to Covid-19. This includes raising awareness about mental and
420 physical health problems of survivors, early interventions, strengthening medical follow
421 up, and increasing physical and psychological rehabilitation capacity.

422 **Author contributions**

423 CH, SZ and JR had full access to all of the data in the study and take responsibility for
424 the integrity of the data and the accuracy of the data analysis. CH, SZ, QG, LY, QW, YY
425 and JR designed the study. WX, XC, YH, DZ, YZ, GZ, SW, YW, ZZ, HL, CZ, BZ, JY, MF,
426 ZN, BC, CD, and HH collected and processed the data. JR, SZ, QG, CH, and YY
427 interpreted the data. JR performed the statistical analysis and wrote the first draft of the

428 manuscript. All other authors revised the manuscript for critical content. All authors
429 reviewed and approved the final submitted version.

430 **Acknowledgment**

431 We thank all the hospital staff members and coordinators under the CSPRM Covid-19
432 network for their efforts in collecting the information that was used in this study;
433 Liangjiang Huang (Tongji Hospital, Tongji Medical College, Huazhong University of
434 Science and Technology), Xu Qin (No.3 People's Hospital of Chengdu), Mingqing Li
435 (Dazhou Central Hospital), Kehui Hu (Suining Central Hospital) ,and Jinling Zhang (West
436 China Second University Hospital, Sichuan University) for their dedication to data entry
437 and verification; Prof. Deying Kang (Epidemiologist, West China Hospital, Sichuan
438 University) and Mrs. Rouyue Fang (Statistician, Industrial and Commercial Bank of
439 China) for their assistance in initial data extraction and processing; all the patients who
440 consented to provide their data for analysis and the medical staff members who are at
441 the frontline caring for patients with Covid-19. We would like to thank Prof. Dr. Gerold
442 Stucki and Cristiana Baffone for constructive comments on an earlier version of the
443 manuscript.

444 **Funding**

445 This study was funded by the National Natural Science Foundation (81972146), the
446 Department of Science and Technology of Sichuan Province (20YYJC3320), China
447 Postdoctoral Science Foundation (2020M673251), Health Commission of Sichuan
448 Province (20PJ034), and West China Hospital of Sichuan University (HX-2019-nCoV-
449 011 to Chengqi He, and 2019HXBH058 to Siyi Zhu). The funders played no role in the
450 design, conduct, or reporting of this study.

451 **Competing interests**

452 The authors declare that they have no competing interests.

453

454

455 **References**

- 456 1. Liang W-h, Guan W-j, Li C-c, Li Y-m, Liang H-r, Zhao Y, et al. Clinical characteristics and
457 outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei
458 (non-epicentre): a nationwide analysis of China. *European Respiratory Journal*. 2020;55(6).
- 459 2. Center for Evidence Based Medicine (CEBM). Global Covid-19 Case Fatality Rates (last
460 updated on June 6 2020) 2020 [cited 2020 Aug 10]. Available from:
461 <https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/>.
- 462 3. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of
463 coronavirus disease 2019 in China. *New England Journal of Medicine*. 2020.
- 464 4. Tucci V, Moukaddam N, Meadows J, Shah S, Galwankar SC, Kapur GB. The Forgotten
465 Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases. *Journal of*
466 *global infectious diseases*. 2017;9(4):151-6. Epub 2018/01/06. doi: 10.4103/jgid.jgid_66_17.
467 PubMed PMID: 29302150; PubMed Central PMCID: PMC5750439.
- 468 5. Griffiths J, Hatch RA, Bishop J, Morgan K, Jenkinson C, Cuthbertson BH, et al. An
469 exploration of social and economic outcome and associated health-related quality of life after
470 critical illness in general intensive care unit survivors: a 12-month follow-up study. *Crit Care*.

- 471 2013;17(3):R100. Epub 2013/05/30. doi: 10.1186/cc12745. PubMed PMID: 23714692; PubMed
472 Central PMCID: PMC3706775.
- 473 6. Wunderink RG, Waterer G. Advances in the causes and management of community
474 acquired pneumonia in adults. *BMJ*. 2017;358:j2471. Epub 2017/07/12. doi: 10.1136/bmj.j2471.
475 PubMed PMID: 28694251.
- 476 7. Fraser E. Long term respiratory complications of covid-19. *British Medical Journal*
477 Publishing Group; 2020.
- 478 8. Gonzalez-Jaramillo N, Low N, Franco OH. The double burden of disease of COVID-19 in
479 cardiovascular patients: overlapping conditions could lead to overlapping treatments. *European*
480 *journal of epidemiology*. 2020;35(4):335.
- 481 9. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and
482 national incidence, prevalence, and years lived with disability for 354 diseases and injuries for
483 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease
484 Study 2017. *The Lancet*. 2018;392(10159):1789-858.
- 485 10. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and
486 national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life
487 expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the
488 Global Burden of Disease Study 2017. *The Lancet*. 2018;392(10159):1859-922.
- 489 11. Tansey CM, Louie M, Loeb M, Gold WL, Muller MP, de Jager J, et al. One-year outcomes
490 and health care utilization in survivors of severe acute respiratory syndrome. *Archives of*
491 *internal medicine*. 2007;167(12):1312-20.

- 492 12. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The
493 psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet*.
494 2020. Epub 2020/03/01. doi: 10.1016/S0140-6736(20)30460-8. PubMed PMID: 32112714.
- 495 13. Siu JY. The SARS-associated stigma of SARS victims in the post-SARS era of Hong Kong.
496 *Qualitative health research*. 2008;18(6):729-38. Epub 2008/05/27. doi:
497 10.1177/1049732308318372. PubMed PMID: 18503014.
- 498 14. National Health Commission of the PR China [国家卫生健康委员会]. Diagnostic criteria
499 of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) [in
500 Chinese; 关于印发新型冠状病毒肺炎诊疗方案（试行第七版）的通知] 2020 [cited 2020
501 March 25]. Available from:
502 <http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml>.
- 503 15. Tong AY, Man DW. The validation of the Hong Kong Chinese version of the Lawton
504 Instrumental Activities of Daily Living Scale for institutionalized elderly persons. *OTJR:
505 Occupation, Participation and Health*. 2002;22(4):132-42.
- 506 16. Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history and
507 prognosis. *Journal of neurology, neurosurgery, and psychiatry*. 1987;50(2):177-82. Epub
508 1987/02/01. doi: 10.1136/jnnp.50.2.177. PubMed PMID: 3572432; PubMed Central PMCID:
509 PMC1031489.
- 510 17. Sze KH, Wong E, Or KH, Lum CM, Woo J. Factors predicting stroke disability at discharge:
511 a study of 793 Chinese. *Archives of physical medicine and rehabilitation*. 2000;81(7):876-80.
512 Epub 2000/07/15. doi: 10.1053/apmr.2000.6279. PubMed PMID: 10895998.

- 513 18. Zung WW. A Rating Instrument For Anxiety Disorders. *Psychosomatics*. 1971;12(6):371-
514 9.
- 515 19. Dunstan DA, Scott N. Norms for Zung's Self-rating Anxiety Scale. *BMC psychiatry*.
516 2020;20(1):90. Epub 2020/03/01. doi: 10.1186/s12888-019-2427-6. PubMed PMID: 32111187;
517 PubMed Central PMCID: PMC7048044.
- 518 20. Zou G. A modified poisson regression approach to prospective studies with binary data.
519 *American journal of epidemiology*. 2004;159(7):702-6.
- 520 21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
521 Coronavirus Disease 2019 in China. *The New England journal of medicine*. 2020. Epub
522 2020/02/29. doi: 10.1056/NEJMoa2002032. PubMed PMID: 32109013.
- 523 22. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and
524 Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice
525 Guideline of the American Thoracic Society and Infectious Diseases Society of America.
526 *American journal of respiratory and critical care medicine*. 2019;200(7):e45-e67. Epub
527 2019/10/02. doi: 10.1164/rccm.201908-1581ST. PubMed PMID: 31573350; PubMed Central
528 PMCID: PMC6812437.
- 529 23. Alger HM, Williams Iv JH, Walchok JG, Bolles MM, Fonarow GC, Rutan C. The Role of Data
530 Registries in the Time of COVID-19. *Circulation Cardiovascular quality and outcomes*. 2020. Epub
531 2020/04/17. doi: 10.1161/circoutcomes.120.006766. PubMed PMID: 32298145.
- 532 24. Cao W-C, De Vlas SJ, Richardus JH. The severe acute respiratory syndrome epidemic in
533 mainland China dissected. *Infectious disease reports*. 2011;3(1).

- 534 25. Batawi S, Tarazan N, Al-Raddadi R, Al Qasim E, Sindi A, Johni SA, et al. Quality of life
535 reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health
536 and quality of life outcomes. 2019;17(1):101.
- 537 26. Lee S, Chan LY, Chau AM, Kwok KP, Kleinman A. The experience of SARS-related stigma
538 at Amoy Gardens. Soc Sci Med. 2005;61(9):2038-46. Epub 2005/05/26. doi:
539 10.1016/j.socscimed.2005.04.010. PubMed PMID: 15913861.
- 540 27. Ryrso CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower
541 mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a
542 systematic review and meta-analysis. BMC pulmonary medicine. 2018;18(1):154. Epub
543 2018/09/17. doi: 10.1186/s12890-018-0718-1. PubMed PMID: 30219047; PubMed Central
544 PMCID: PMC6139159.
- 545 28. Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM. Increasing implementation
546 and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement.
547 The European respiratory journal. 2016;47(5):1336-41. Epub 2016/05/02. doi:
548 10.1183/13993003.02151-2015. PubMed PMID: 27132269.
- 549 29. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a
550 novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak.
551 Emerging Microbes and Infections. 2020;9(1):313-9. PubMed PMID: 2004238813.
- 552 30. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
553 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
554 study. Lancet. 2020;395(10223):507-13. Epub 2020/02/03. doi: 10.1016/s0140-6736(20)30211-
555 7. PubMed PMID: 32007143; PubMed Central PMCID: PMCPMC7135076.

- 556 31. Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, et al. Factors Associated With Mental Health
557 Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA network
558 open. 2020;3(3):e203976. Epub 2020/03/24. doi: 10.1001/jamanetworkopen.2020.3976.
559 PubMed PMID: 32202646; PubMed Central PMCID: PMC7090843.
- 560 32. Mak IWC, Chu CM, Pan PC, Yiu MGC, Chan VL. Long-term psychiatric morbidities among
561 SARS survivors. General hospital psychiatry. 2009;31(4):318-26.
- 562 33. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
563 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.
564 2020;395(10229):1054-62. Epub 2020/03/15. doi: 10.1016/S0140-6736(20)30566-3. PubMed
565 PMID: 32171076.
- 566 34. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its
567 impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory
568 Journal. 2020;55(5).
- 569 35. WHO. International Classification of Functioning, Disability, and Health. Geneva: WHO
570 Press; 2001.
- 571 36. Armitage R, Nellums LB. The COVID-19 response must be disability inclusive. The Lancet
572 Public Health. 2020;5(5):e257.
- 573 37. WHO. Disability considerations during the COVID-19 outbreak: World Health
574 Organization; 2020 [cited 2020 Aug 10]. Available from:
575 [https://apps.who.int/iris/bitstream/handle/10665/332015/WHO-2019-nCov-Disability-2020.1-](https://apps.who.int/iris/bitstream/handle/10665/332015/WHO-2019-nCov-Disability-2020.1-eng.pdf)
576 [eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/332015/WHO-2019-nCov-Disability-2020.1-eng.pdf).

- 577 38. Solomon MZ, Wynia MK, Gostin LO. Covid-19 crisis triage—optimizing health outcomes
578 and disability rights. *New England Journal of Medicine*. 2020.
- 579 39. Giummarra MJ, Lennox A, Dali G, Costa B, Gabbe BJ. Early psychological interventions for
580 posttraumatic stress, depression and anxiety after traumatic injury: A systematic review and
581 meta-analysis. *Clinical psychology review*. 2018;62:11-36. Epub 2018/05/14. doi:
582 10.1016/j.cpr.2018.05.001. PubMed PMID: 29754102.
- 583 40. Zhang L, Hu W, Cai Z, Liu J, Wu J, Deng Y, et al. Early mobilization of critically ill patients
584 in the intensive care unit: A systematic review and meta-analysis. *PLoS One*.
585 2019;14(10):e0223185. Epub 2019/10/04. doi: 10.1371/journal.pone.0223185. PubMed PMID:
586 31581205; PubMed Central PMCID: PMC6776357.
- 587 41. Xiao Y, Zhao K, Ma ZX, Li X, Qiu YP. Integrated medical rehabilitation delivery in China.
588 *Chronic diseases and translational medicine*. 2017;3(2):75-81. Epub 2017/10/25. doi:
589 10.1016/j.cdtm.2017.02.003. PubMed PMID: 29063059; PubMed Central PMCID: PMC5627700.

590

591

592 **Supporting information**

593 **Table S1. Outcome: One or more IADL problems (Lawton IADL scale, at least one**
594 **item endorsed)[&]. [&]n= 431 for adjusted model and unadjusted model for age, n= 432 for
595 all other models. RR = Risk Ratio. CI = Confidence Interval.**

596
597 **Table S2. Outcome: At least moderate ADL dependence (Barthel Index, < 75)[&]. [&]n=
598 431 for adjusted model and unadjusted model for age, n= 432 for all other models. RR =
599 Risk Ratio. CI = Confidence Interval.**


600
601 **Table S3. Outcome: Anxiety (Zung's self-reported anxiety scale, raw score < 40)[&].**
602 [&]n=407 for adjusted model and n=407 for unadjusted model for length of stay, n= 431 for
603 unadjusted model for age, n= 432 for all other models. RR = Risk Ratio. CI = Confidence
604 Interval.

605

606

607

1. Presence of IADL limitations (at least one)



2. ADL dependence (at least moderate)

